Tango Therapeutics, Inc.NASDAQ: TNGX

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

· Issued by Tango Therapeutics, Inc. via GlobeNewswire

Summary by 6ix AI

Tango Therapeutics, a clinical-stage biotechnology company developing cancer therapies, granted a new employee an option to buy 146,500 shares of common stock and 40,000 restricted stock units (RSUs) under its 2023 Inducement Plan, effective September 1, 2026.

Key details

  • The grant was made by the Compensation Committee of Tango Therapeutics' Board of Directors under the 2023 Inducement Plan, pursuant to Nasdaq Listing Rule 5635(c)(4); the plan is used only for equity awards given as an inducement to a person entering employment with Tango Therapeutics.
  • The options have an exercise price of $22.35 per share, equal to the closing price of Tango Therapeutics' common stock on September 1, 2026.
  • The options vest 25% on the first anniversary of the employee's start date, then an additional 1/36th of the remaining shares monthly, subject to continued employment.
  • The RSUs vest in three equal annual installments, subject to continued employment.

What’s still pending

  • Vesting of both the options and the RSUs depends on the employee's continued employment on each vesting date.

6ix AI wrote this summary from the release below and checked it against the release.

On 6ix: 6ix.com/news/tango-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-4

BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (Tango Therapeutics or the Company) today announced that, effective September 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 146,500 shares of its common stock and 40,000 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan.

The Tango Therapeutics 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individual's entering into employment with Tango Therapeutics, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

The options have an exercise price of $22.35 per share, which is equal to the closing price of Tango Therapeutics' common stock on September 1, 2026. Each option will vest as to 25% of the shares underlying such option on the first anniversary of the employee’s start date and as to an additional 1/36th of the remaining shares underlying the option monthly thereafter, in each case, subject to the employee's continued employment on each vesting date. The RSU award will vest in three equal annual installments, subject to the employee's continued employment on each vesting date. The options and RSUs are subject to the terms and conditions of Tango Therapeutics' 2023 Inducement Plan, which was approved in February 2023, and the terms and conditions of the stock option and RSU agreements covering the grant.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com.

Investors:
Elizabeth Hickin
ehickin@tangotx.com

Media:
1AB
Amanda Lazaro
amanda@1abmedia.com

Tango Therapeutics, Inc. on 6ix

Earlier from Tango Therapeutics

Later from Tango Therapeutics

All Tango Therapeutics news releases